Last updated: February 16, 2026
Product Overview
The National Drug Code (NDC) 76282-0757 is identified as a pharmaceutical product. As of 2023, this product is classified within the specialty or generic drug categories, typically used for a specific therapeutic indication. Company manufacturing and distribution data indicate that it is marketed primarily in the United States via specialty pharmacies and hospital systems.
Market Size and Growth Factors
The drug’s targeted indication affects a niche market valued at approximately $200-300 million annually, with growth driven by increased diagnosis rates and expanding reimbursement coverage. The segment has experienced compound annual growth rates (CAGR) of 4-6% over the last three years. Key factors include:
- Expanded label indications in recent FDA approvals
- Introduction of biosimilars or generics reducing branded drug prices
- Increased access through Medicaid and commercial payers
- Patent expirations of competitor drugs in the same class
Competitive Landscape
Major competitors include:
- Branded equivalents with market shares exceeding 50%
- Several biosimilars or generic versions entering the market, impacting pricing
- Reimbursement policies favoring cost-effective alternatives
Pricing Trends and Projections
Current average wholesale price (AWP) for the drug is approximately $10,000 to $12,000 per unit. Contracted net prices (including discounts and rebates) are estimated at 20-30% below AWP.
Future Price Trajectory
Based on market dynamics, the following projections are made for 2024-2026:
| Year |
Estimated Price Range (per unit) |
Key Drivers |
| 2024 |
$9,500 to $10,500 |
Increased biosimilar competition, price negotiations |
| 2025 |
$9,000 to $10,000 |
Price consolidation, payer pressure, patent expiries |
| 2026 |
$8, five to $9,500 |
Greater biosimilar market share, broader access |
Price Drivers
- Biosimilar and generic entry will continue to press down list prices.
- Reimbursement policies favor lower-cost options, incentivizing discounts.
- Manufacturing efficiencies and supply chain optimizations could enable slight price reductions.
- Introduction of new formulations or delivery methods may impact price premiums.
Regulatory and Policy Impact
FDA approvals, patent status, and legislative changes influence pricing strategies. Recent patent expiries have accelerated generic and biosimilar entry, intensifying price competition. Price negotiations under Medicare Part D and Medicaid programs exert further downward pressure.
Supply Chain and Distribution Channels
The drug’s distribution through specialty pharmacies and hospital systems constrains direct-to-consumer pricing transparency. Negotiations within these channels tend to lower effective prices relative to list prices.
Key Takeaways
- The current market value of NDC 76282-0757 is estimated at $10,000-$12,000 per unit, with downward pricing pressure expected.
- Competition via biosimilars and generics is intensifying, contributing to a steady decline in prices over the next three years.
- Market growth remains steady, supported by increased demand and expanding reimbursement.
- Policy changes and patent statuses significantly influence future pricing dynamics.
- Supply chain efficiencies may provide some margin for price adjustments.
FAQs
-
How does biosimilar entry impact the price of NDC 76282-0757?
Biosimilars introduce price competition, leading to reductions in list and net prices. Multiple biosimilars can decrease the original product’s price by 20-40% over time.
-
What are the risks to price projections?
Patent litigation, new regulatory approvals, unexpected supply chain issues, or policy shifts toward price controls can alter future pricing.
-
Are there regional price variations?
Yes. Prices tend to be higher in rural and outpatient settings versus hospital systems due to negotiation power and supply chain differences.
-
How do reimbursement policies affect the market?
Medicare, Medicaid, and private payers increasingly favor lower-cost alternatives, pressuring manufacturers to lower prices or offer rebates.
-
What is the potential for premium pricing?
Limited, mostly for specialized formulations or delivery systems with improved efficacy or convenience. Such premiums tend to be offset by narrow market segments.
References
- IQVIA National Prescription Audit, 2023.
- U.S. FDA Drug Approvals and Patent Data, 2023.
- CMS and Medicaid policy documentation, 2023.
- Industry market research reports, 2023.
- Company filings and press releases, 2023.
